Search results for "Statins"
Rosuvastatin appears better than atorvastatin for mortality, cardio, liver outcomes in large database
Six-year all-cause mortality was lower among patients taking rosuvastatin than atorvastatin, but the difference was only about a percentage point, a study of patients in the United Kingdom and China found.
https://immattersacp.org/weekly/archives/2024/10/29/5.htm
29 Oct 2024
Statins not commonly used among younger cohorts even after ASCVD diagnosis
Among patients ages 18 to 44 years diagnosed with atherosclerotic cardiovascular disease (ASCVD), statin use changed from 18.34% in 1999 to 16.63% in 2020, according to data from the National Health and Nutrition Examination Survey.
https://immattersacp.org/weekly/archives/2024/08/20/4.htm
20 Aug 2024
Statins safe, offer benefits even in very old patients
Reductions in cardiovascular disease (CVD) after statin therapy were seen in patients up to ages 85 years or older without increasing risks for severe adverse effects.
https://immattersacp.org/weekly/archives/2024/05/28/1.htm
28 May 2024
U.S. statin use plateaued in 2013 to 2018
Most U.S. adults with the strongest guideline recommendations for primary prevention with statins are not receiving them, including those with diabetes, extremely high cholesterol levels, or 10-year risk of cardiovascular disease over 20%, a study found.
https://immattersacp.org/weekly/archives/2023/12/05/1.htm
5 Dec 2023
Rosuvastatin, atorvastatin compared on effectiveness, safety in industry-funded trial
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.
https://immattersacp.org/weekly/archives/2023/10/24/4.htm
24 Oct 2023
Statins underused in patients with cardiovascular disease, study finds
Women, older adults, and those with peripheral artery disease and cerebrovascular disease are particularly likely not to receive statins, according to an industry-funded analysis of lipid-lowering therapy use.
https://immattersacp.org/weekly/archives/2023/08/08/2.htm
8 Aug 2023
Statins rarely cause muscle pain, meta-analysis finds
Statin therapy caused approximately 11 reports of any muscle pain or weakness per 1,000 treated patients during the first year of use, but little after, according to an analysis of placebo-controlled trials and trials of more intensive versus less intensive statin therapy.
https://immattersacp.org/weekly/archives/2022/09/06/4.htm
6 Sep 2022
Study finds no difference in muscle symptom scores between statin, placebo
Three months after 200 primary care patients in the U.K. who previously reported muscle symptoms from statins underwent a series of randomized, placebo-controlled, n-of-one trials, about two-thirds said they planned to restart statin treatment.
https://immattersacp.org/weekly/archives/2021/03/02/2.htm
2 Mar 2021
Statins not associated with memory or cognition decline in elderly
Statins were associated with preserved cognitive ability in some subgroups, and the study may offer reassurance to patients concerned about statins' effects on the brain, study authors wrote.
https://immattersacp.org/weekly/archives/2019/11/19/4.htm
19 Nov 2019
Lipophilic statins associated with significantly reduced hepatocellular carcinoma incidence, mortality in hepatitis
Potential benefits of lipophilic statins appeared to be dose- and duration-dependent, with the greatest reduction in hepatocellular carcinoma risk seen with use of a moderate-dose statin for about two years, according to data from a registry of Swedish patients with hepatitis B or C.
https://immattersacp.org/weekly/archives/2019/08/20/1.htm
20 Aug 2019
Statins appear to benefit all ages, may be less helpful for primary prevention in the elderly
A meta-analysis by the Cholesterol Treatment Trialists' Collaboration looked at the effect of statins on major vascular events, cause-specific mortality, and cancer incidence.
https://immattersacp.org/weekly/archives/2019/02/12/4.htm
12 Feb 2019
Statins may be significantly overprescribed for primary prevention, computer model suggests
An analysis compared risk of drug-related events, including myopathy, hepatic dysfunction, and incident diabetes, to predicted cardiovascular benefit for men and women at various ages.
https://immattersacp.org/weekly/archives/2018/12/04/1.htm
4 Dec 2018
Continuing statins after adverse event associated with reduced risk for death
The study's findings may help physicians engage in a balanced discussion with patients about the benefits and risks of continuing statin therapy after an adverse reaction.
https://immattersacp.org/weekly/archives/2017/07/25/1.htm
25 Jul 2017
Statins often not prescribed in younger patients with dyslipidemia, study finds
Patients who had at least one indication for statin therapy were analyzed according to the following groups: LDL cholesterol level of at least 190 mg/dL, diabetes and LDL cholesterol level above 70 mg/dL, and atherosclerotic cardiovascular disease.
https://immattersacp.org/weekly/archives/2017/01/10/2.htm
10 Jan 2017
USPSTF issues recommendations on statins for primary prevention
Among other recommendations, low- to moderate-dose statins should be started in adults 40 to 75 years of age who have no history of cardiovascular disease (CVD) but have at least 1 risk factor and a 10-year CVD event risk calculated at 10% or more.
https://immattersacp.org/weekly/archives/2016/11/22/1.htm
22 Nov 2016
USPSTF issues recommendations on statins for primary prevention
Among other recommendations, low- to moderate-dose statins should be started in adults 40 to 75 years of age who have no history of cardiovascular disease (CVD) but have at least 1 risk factor and a 10-year CVD event risk calculated at 10% or more.
https://immattersacp.org/weekly/archives/2016/11/15/1.htm
15 Nov 2016
Measure of coronary artery calcium might spare statins in some elderly patients
Coronary artery calcium-guided reclassification improved specificity for coronary heart disease events by 22% without any significant loss in sensitivity, while reclassification based on carotid plaque burden improved specificity 16% with a 7% loss in sensitivity, a study found.
https://immattersacp.org/weekly/archives/2016/08/23/1.htm
23 Aug 2016
Intensive-dose statins don't confer greater diabetes risk for post-MI elderly than moderate doses
Older patients with myocardial infarction (MI) who take intensive-dose statins have the same risk of developing diabetes as those who take moderate-dose statins, a new study found.
https://immattersacp.org/weekly/archives/2013/05/21/5.htm
21 May 2013
Model may predict which coronary artery disease patients benefit from high-dose statins
Incremental treatment effects of high-dose statin therapy over usual-dose statin therapy in coronary artery disease patients can be estimated by a prediction model made up of 13 easy-to-measure clinical predictors that are readily available in clinical practice, a study concluded.
https://immattersacp.org/weekly/archives/2013/05/21/4.htm
21 May 2013
Lower energy, more exertional fatigue with statins
Statin treatment was associated with less energy and more exertional fatigue, according to a recent analysis.
https://immattersacp.org/weekly/archives/2012/06/19/5.htm
19 Jun 2012